Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jul;33(3):470-475.
doi: 10.1007/s13577-020-00377-z. Epub 2020 May 23.

Progress in the treatment of osteoarthritis with umbilical cord stem cells

Hanguang Liang  1 , Haiqiang Suo  1 , Zhiwei Wang  1 , Wei Feng  2
Affiliations
Review

Progress in the treatment of osteoarthritis with umbilical cord stem cells

Hanguang Liang et al. Hum Cell. 2020 Jul.

Abstract

Osteoarthritis is a chronic degenerative joint disease with an incidence of 81% among people aged over 65 years in China. Osteoarthritis significantly decreases the quality of life of patients, causing physical and psychological damage and posing a serious economic burden. Clinical treatments for osteoarthritis include drug and surgical treatments. Drug treatment can successfully alleviate pain but not satisfactorily reverse joint damage, while surgical intervention is typically used to treat end-stage disease. Stem cells are multi-potential progenitor cells with self-renewal and multi-lineage differentiation abilities, and can differentiate into many kinds of cells, including chondrocytes. Umbilical cord stem cells, also known as Wharton's jelly mesenchymal stem cells (WJ-MSCs), have become the first choice for cartilage regeneration engineering owing to their availability and convenience of collection. This article reviews the biological characterization of WJ-MSCs in recent years, their advantages compared with other stem cells, and their application in the treatment of osteoarthritis in animal experiments and clinical trials.

Keywords: Chondrogenesis; Osteoarthritis; Regeneration engineering; Tissue engineering; Umbilical cord stem cells.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

References

    1. Bijlsma JWJ, Berenbaum F, Lafeber FPJG. Osteoarthritis: an update with relevance for clinical practice. Lancet. 2011;377(9783):2115–2126. doi: 10.1016/S0140-6736(11)60243-2. - DOI - PubMed
    1. Ding DC, Wu KC, Chou HL, et al. Human infrapatellar fat pad-derived stromal cells have more potent differentiation capacity than other mesenchymal cells and can be enhanced by hyaluronan. Cell Transplant. 2014;24(7):1221–1232. doi: 10.3727/096368914X681937. - DOI - PubMed
    1. Khan WS, Adesida AB, Tew SR, Longo UG, Hardingham TE. Fat pad-derived mesenchymal stem cells as a potential source for cell-based adipose tissue repair strategies. Cell Prolif. 2012;45(2):111–120. doi: 10.1111/j.1365-2184.2011.00804.x. - DOI - PMC - PubMed
    1. Rebecca W, Khan IM, Kirsty R, et al. Identification and clonal characterisation of a progenitor cell sub-population in normal human articular cartilage. PLoS ONE. 2010;5(10):e13246. doi: 10.1371/journal.pone.0013246. - DOI - PMC - PubMed
    1. Ziaei M, Zhang J, Patel DV, McGhee CNJ. Umbilical cord stem cells in the treatment of corneal disease. Surv Ophthalmol. 2017;62(6):803. doi: 10.1016/j.survophthal.2017.02.002. - DOI - PubMed